Document:

Exhibit 10.1

 

 

SUBSCRIPTION AGREEMENT

 

This Subscription
Agreement (this “Agreement”) is made as of December 20, 2016, by and among Bionik
Laboratories Corp., a Delaware corporation (the “Company”), and the subscribers identified
on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”).

 

Recitals

 

Whereas,
the Company seeks to sell a maximum of US$1,500,000 (the “Total Amount”) in Convertible Promissory Notes
in the form annexed hereto as Exhibit A (each, a “Note”
and collectively, the “Notes”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”), Rule 506(b) of Regulation D (“Regulation D”) and/or
Regulation S (“Regulation S”) as promulgated under the Securities Act (the “Offering”);
and

 

Whereas,
the Subscribers wishes to purchase Notes in the amount set forth on (the “Subscription Amount”), and
in accordance with the lending percentages set forth opposite their respective names on (each, a “Proportionate Percentage”),
their respective Signature Page to this Agreement.

 

Now,
Therefore, in consideration of
the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Company and the Subscribers hereby agree as follows:

 

		1.	PURCHASE OF CONVERTIBLE PROMISSORY NOTES.

 

1.1             
Subscription. Subject to the terms and conditions herein, the Subscribers
will loan to the Company, and the Company shall borrow from the Subscribers, in accordance with the Proportionate Percentage: (a)
on or about December 20, 2016, an aggregate of US$500,000; (b) on January 16, 2017, an aggregate of US$500,000; and (c) on February
15, 2017, an aggregate of US$500,000 (each such date, a “Funding Date”). Notwithstanding the foregoing,
in the event the Company raises aggregate gross proceeds from the sale of the Notes hereunder plus the sale its equity securities
in an amount equal to or in excess of US$5,000,000 before one or more of the Funding Dates, the Subscribers shall not be obligated
to lend, and the Company shall not borrow, the funds otherwise to be loaned on such future Funding Date(s); provided, however,
if the Company raises aggregate gross proceeds (excluding the sale of the Notes hereunder) in an amount equal to or in excess of
US$1,500,000 but less than US$3,000,000, then in such case, the Subscribers shall nevertheless be obligated to lend the funds otherwise
to be loaned on such future Funding Dates if requested by the Company.

 

1.2             
Payment for Subscription. Each Subscriber agrees that the Subscription
Amount to the Company for the amount of the Subscriber’s Subscription is to be made upon the Initial Closing (as defined
below) and on each additional Closing (as defined below), by check or by wire transfer to an account designated by the Company.

 

     

     

    

 

		1.3	Closing.

 

(a)              
The closing of the subscriptions for the Notes shall occur on each Funding Date (collectively, the “Closings”
and each, without distinction, a “Closing”). Each Closing shall be held remotely by the electronic exchange
of documents and funds, at 10:00 a.m. Eastern Time, or at such other time and by such means upon which the Company and the Subscribers
purchasing the Notes at such Closing shall agree.

 

(b)              
The first such Closing (the “Initial Closing”) for an aggregate amount of US$500,000 in Principal
Amount of Notes shall take place on or about December 20, 2016.

 

(c)               
At each Closing, the Company shall deliver to the Subscribers executed Notes in the amounts determined for each Purchaser
pursuant to this Section 1.

 

		2.	REPRESENTATIONS AND WARRANTIES.

 

		2.1	Representations
and Warranties by the Company. The Company represents and warrants to each Subscriber that:

 

(a)              
Authorization. The Company has all corporate right, power and authority to enter into this Agreement and to consummate
the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary
for the: (i) authorization execution, delivery and performance of this Agreement by the Company; (ii) authorization, sale, issuance
and delivery of the Notes contemplated hereby and the performance of the Company’s obligations hereunder; and (iii) authorization,
issuance and delivery of the securities issuable upon conversion of the Notes, has been taken. The securities issuable upon conversion
of the Notes will be validly issued, fully paid and nonassessable.

 

(b)              
Enforceability. Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties
hereto and thereto other than the Company, this Agreement is duly authorized, executed and delivered by the Company constitutes
the legal, valid and binding obligations of the Company enforceable against the Company in accordance with its terms, except as
such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the
enforcement of creditors rights generally.

 

(c)               
No Violations. The execution, delivery and performance of this Agreement and the Notes by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Certificate of Incorporation
of the Company or other organizational documents of the Company, (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree applicable to the Company by which any property or asset of the Company is bound
or affected.

 

    2

     

    

 

2.2          Disclaimer. It is specifically understood and agreed by each Subscriber
that the Company has not made, nor by this Agreement shall be construed to make, directly or indirectly, explicitly or by implication,
any representation, warranty, projection, assumption, promise, covenant, opinion, recommendation or other statement of any kind
or nature with respect to the anticipated profits or losses of the Company, except as otherwise provided with this Agreement.

 

		2.3	Representations
and Warranties by the Subscribers. Each Subscriber represents and warrants to the Company that:

 

(a)              
The Subscriber is acquiring the Notes for the Subscriber’s own account, as principal, for investment purposes
only and not with any intention to resell, distributes or otherwise dispose of the Notes, in whole or in part.

 

(b)              
The Subscriber has had an unrestricted opportunity to: (i) obtain information concerning the Offering, including the
Notes, the Company and its proposed and existing business and assets; and (ii) ask questions of, and receive answers from the Company
concerning the terms and conditions of the Offering and to obtain such additional information as may have been necessary to verify
the accuracy of the information contained in the this Agreement or otherwise provided.

 

(c)               
The Subscriber has such knowledge and experience in financial and business matters that he is capable of evaluating
the merits and risks of investing in the Company, and all information that the Subscriber has provided concerning the Subscriber,
the Subscriber’s financial position and knowledge of financial and business matters is true, correct and complete.

 

(d)              
The Subscriber has relied solely on the advice of, or has consulted with, in regard to the legal, investment and tax
considerations involved in the purchase, ownership and disposition of Notes, the Subscriber’s own legal counsel, business
and/or investment adviser, accountant and tax adviser.

 

    3

     

    

 

(e)               
If the Subscriber is an entity, the Subscriber is duly organized, validly existing and in good standing under the laws
of its jurisdiction of incorporation or organization, as the case may be. The Subscriber has all requisite power and authority
to own its properties, to carry on its business as presently conducted, to enter into and perform this Agreement, the Notes and
the agreements, documents and instruments executed, delivered and/or contemplated hereby (collectively, the “Subscription
Documents”) to which it is a party and to carry out the transactions contemplated hereby and thereby. The Subscription
Documents are valid and binding obligations of the Subscriber, enforceable against it in accordance with their terms, except as
enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time
in effect, which affect enforcement of creditors’ rights generally. If applicable, the execution, delivery and performance
of the Subscription Documents to which it is a party have been duly authorized by all necessary action of the Subscriber. The execution,
delivery and performance of the Subscription Documents and the performance of any transactions contemplated by the Subscription
Documents will not: (i) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both)
under any contract or obligation to which the Subscriber is a party or by which it or its assets are bound, or any provision of
its organizational documents (if an entity), or cause the creation of any lien or encumbrance upon any of the assets of the Subscriber;
(ii) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under, any provision
of any law, regulation or rule, or any order of, or any restriction imposed by any court or other governmental agency applicable
to the Subscriber; (iii) require from the Subscriber any notice to, declaration or filing with, or consent or approval of any governmental
authority or other third party other than pursuant to federal or state securities or blue sky laws; or (iv) accelerate any obligation
under, or give rise to a right of termination of, any agreement, permit, license or authorization to which the Subscriber is a
party or by which it is bound.

 

(f)               
At the time the Subscriber was offered the Notes, it was, and at the date hereof it is, and on each Funding Date and
date on which the Subscriber converts the Notes the Subscriber will be, an “accredited investor” as defined in Rule
501(a) under the Securities Act. The Subscriber hereby represents that neither the Subscriber nor any of its Rule 506(d) Related
Parties is a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities Act. For purposes of this
Agreement, “Rule 506(d) Related Party” shall mean a person or entity covered by the “Bad Actor
disqualification” provision of Rule 506(d) of the Securities Act.

 

		3.	MISCELLANEOUS.

 

3.1           Addresses and Notices. All notices, demands, consents, requests, instructions
and other communications to be given or delivered or permitted under or by reason of the provisions of this Agreement or in connection
with the transactions contemplated hereby shall be in writing and shall be deemed to be delivered and received by the intended
recipient as follows: (i) if personally delivered, on the business day of such delivery (as evidenced by the receipt of the personal
delivery service); (ii) if mailed certified or registered mail return receipt requested, two (2) business days after being mailed;
or (iii) if delivered by overnight courier (with all charges having been prepaid), on the business day of such delivery (as evidenced
by the receipt of the overnight courier service of recognized standing). If any notice, demand, consent, request, instruction or
other communication cannot be delivered because of a changed address of which no notice was given (in accordance with this Section
3.1, or the refusal to accept same, the notice, demand, consent, request, instruction or other communication shall be deemed
received on the second business day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands,
consents, requests, instructions and other communications will be sent to the following addresses or facsimile numbers as applicable:

 

	 	If to the Company to:	 	
        Bionik Laboratories Corp.

        483 Bay Street, N105

        Toronto, ON M5G 2C9

        Attention: Peter Bloch

	 	 	 	 
	 	With copies to:	 	
        Ruskin Moscou Faltischek, PC

        1425 RXR Plaza

        East Tower, 15th Floor

        Uniondale, New York 11576

        Attention: Stephen E. Fox, Esq.

 

    4

     

    

 

If to the Subscriber, to the address set
forth on the signature page annexed hereto.

 

Any such person may by notice given in
accordance with this Section 3.1 to the other parties hereto designate another address or person for receipt by such person
of notices hereunder.

 

3.2             
Titles and Captions. All Article and Section titles or captions in this
Agreement are for convenience only. They shall not be deemed part of this Agreement and do not in any way define, limit, extend
or describe the scope or intent of any provisions hereof.

 

3.3             
Assignability. This Agreement is not transferable or assignable by the
undersigned.

 

3.4             
Pronouns and Plurals. Whenever the context may require, any pronoun used
herein shall include the corresponding masculine, feminine or neuter forms. The singular form of nouns, pronouns and verbs shall
include the plural and vice versa.

 

3.5             
Further Action. The parties shall execute and deliver all documents, provide
all information and take or forbear from taking all such action as may be necessary or appropriate to achieve the purposes of this
Agreement. Each party shall bear its own expenses in connection therewith.

 

3.6             
Applicable Law. This Agreement shall be construed in accordance with and
governed by the laws of the State of Delaware without regard to its conflict of law rules.

 

3.7             
Binding Effect. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective heirs, administrators, successors, legal representatives, personal representatives,
permitted transferees and permitted assigns. If the undersigned is more than one person, the obligation of the undersigned shall
be joint and several and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be
made by and be binding upon each such person and such person’s heirs, executors, administrators and successors.

 

3.8             
Integration. This Agreement, together with the remainder of the Subscription
Documents of which this Agreement forms a part, constitutes the entire agreement among the parties pertaining to the subject matter
hereof and supersedes and replaces all prior and contemporaneous agreements and understandings, whether written or oral, pertaining
thereto. No covenant, representation or condition not expressed in this Agreement shall affect or be deemed to interpret, change
or restrict the express provisions hereof.

 

    5

     

    

 

3.9           Amendment.  This Agreement and the Notes may be amended only with the
written consent of the Company and the holders of a majority of the aggregate principal amount of the Notes (a “Majority
in Interest”). The conditions or observance of any term of this Agreement may be waived (either generally or in a
particular instance and either retroactively or prospectively) only by written instrument and with respect to conditions or performance
obligations benefiting the Company, by the Company, and with respect to conditions or performance obligations benefiting the Subscribers,
only with the consent of a Majority in Interest. Any amendment or waiver effected in accordance with this Section 3.9 shall
be binding on all holders of the Notes, even if they do not execute such amendment, consent or waiver, as the case may be.

 

3.10         Creditors.  None of the provisions of this Agreement shall be for the
benefit of or enforceable by creditors of any party.

 

3.11         Waiver.  No failure by any party to insist upon the strict performance
of any covenant, agreement, term or condition of this Agreement or to exercise any right or remedy available upon a breach thereof
shall constitute a waiver of any such breach or of such or any other covenant, agreement, term or condition.

 

3.12         Rights and Remedies. The rights and remedies of each of the parties hereunder
shall be mutually exclusive, and the implementation of one or more of the provisions of this Agreement shall not preclude the implementation
of any other provision.

 

3.13         Counterparts. This Agreement may be executed in one or more counterparts,
each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to
constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

 

signatures
on the following pages

 

 

    6

     

    

 

In
Witness Whereof, the undersigned has executed this Agreement on this 20th day of December, 2016.

 

	Signature of Subscriber:

	
        

	 	 
	 	 	 	 
	By:	 	 	Print Name of Subscriber
	Name:	 	 	 
	Title:	 	 	 
	 	 	 	 
	 	 
	Social Security Number(s) or EIN	 

 

	Mailing Address of Subscriber(s)	 	Residence of Subscriber(s)	 
	 	 	 	 
		 		 
	Street	 	Street	 
	 	 	 	 
		 		 
	City          State          Zip
    Code	 	City          State          Zip
Code 
	 

 

If Joint Ownership, check one:      

 

	 ̈	Joint Tenants with Right of Survivorship	 	 	 
	 ̈	Tenants-in-Common	 	 	 
	 ̈	Tenants by the Entirety	 	 	 
	 ̈	Community Property	 	 	 
	 ̈	Other (specify):  ___________________	 	 	 
	 	 	 	 	 
	 	 	 	Proportionate Percentage:____%	 
	 	 	 	 	 
	 	 	 	$______________________________	 
	 	 	 	Aggregate Subscription Amount	 
	 	 	 	 	 
	 	 	 	Method of Payment:  x Wire Transfer     ̈ Check	 

  

FOREGOING SUBSCRIPTION ACCEPTED:

 

Bionik
Laboratories Corp.

 

	 	 	 	 
	By:  	/s/ Peter Bloch	 	
	Name:  Peter Bloch	 	 
	Title:  Chairman and CEO	 	 

 

 

Signature
Page to Subscription Agreement 

    7Exhibit 10.2

 

  

THIS NOTE HAS NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY
NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM,
THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS.

 

 

 

BIONIK LABORATORIES CORP.

 

CONVERTIBLE PROMISSORY NOTE

 

	Principal Amount: US$[_____] 	Issue Date: [_____]

 

Bionik
Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises
to pay to [_____] or his permitted assigns or successors (the “Holder”), the principal amount of [_____]
Dollars (US$[___]) (the “Principal Amount”), without demand, on the Maturity Date (as hereinafter defined),
together with any accrued and unpaid interest due thereon. This Note shall bear interest at a fixed rate of 6% per annum, beginning
on the Issue Date. Interest shall be computed based on a 360-day year of twelve 30-day months and shall be payable, along with
the Principal Amount, on the Maturity Date. Except as set forth in Section 3.1, payment of all principal and interest due
shall be in such coin or currency of the United States of America as shall be legal tender for the payment of public and private
debts at the time of payment.

 

This Note is a convertible
promissory note referred to in that certain Subscription Agreement dated as of the date hereof, or series of like subscription
agreements (the “Subscription Agreement”), among the Company and the subscribers named therein, pursuant
to which the Company is seeking to borrow up to $1,500,000.

 

		1.	Definitions.

 

1.1             
Definitions. The terms defined in this Section 1 whenever used
in this Note shall have the respective meanings hereinafter specified.

 

“Change
in Control”  means a merger or consolidation of the Company with or into any other entity in which the stockholders
of the Company immediately prior to the merger or consolidation do not own more than 50% of the outstanding voting power (assuming
conversion of all convertible securities and the exercise of all outstanding options and warrants) of the surviving entity or the
sale, lease, licensing, transfer or other disposition of all or substantially all the assets of the Company; provided, however,
that any new issuance of capital stock (or securities convertible or exercisable into capital stock) of the Company to one or more
third parties for the sole purpose of providing funding for the Company shall not constitute a Change in Control.

 

“Common
Stock” means the common stock, par value $0.001 per share, of the Company.

 

     

     

    

 

“Conversion
Shares” means the New Round Stock issued or issuable to the Holder upon a Conversion Date pursuant to Article
3.

 

“Conversion
Date” shall mean the date, if any, of the conversion of this Note into Conversion Shares, as provided in Section
3.1.

 

“Event
of Default” shall have the meaning set forth in Section 6.1.

 

“Holder”
or “Holders” means the person named above or any Person who shall thereafter become a recordholder of
this Note in accordance with the terms hereof.

 

“Issue
Date” means the issue date stated above.

 

“Maturity
Date” shall mean the earlier of: (a) March 31, 2017 and (b) the consummation of a Qualified Financing.

 

“New Round
Stock” means, in the event of a Qualified Financing, the securities (or units of securities if more than one security
are sold as a unit) issued by the Company in the Qualified Financing.

 

“Note”
means this Convertible Note, as amended, modified or restated.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization
or any government, governmental department or agency or political subdivision thereof.

 

“Premium”
means, with respect to the repayment or conversion of the Principal Amount, an amount equal to ten percent (10%) of the Principal
Amount less the interest accrued and unpaid through the measurement date.

 

“Securities
Act” means the United States Securities Act of 1933, as amended.

 

“Tier 1
Qualified Financing” means the next equity or equity-linked round of financing of the Company in whatever form or
type that raises gross proceeds of $5,000,000 or more, less the aggregate amount raised by the Company pursuant to the Subscription
Agreement.

 

“Tier 2
Qualified Financing” means the next equity or equity-linked round of financing of the Company in whatever form or
type that raises gross proceeds of $3,500,000 or more and less than $5,000,000, less the aggregate amount raised by the Company
pursuant to the Subscription Agreement.

 

“Tier 3
Qualified Financing” means the next equity or equity-linked round of financing of the Company in whatever form or
type that raises gross proceeds of less than $3,500,000, less the aggregate amount raised by the Company pursuant to the Subscription
Agreement.

 

“Trading
Market” means the OTCQX market place of the OTC Markets; provided however, that in the event the Company’s
Common Stock is ever listed or traded on the New York Stock Exchange, the NYSE Amex Equities, the Nasdaq Global Select Market,
the NASDAQ Global Market, the NASDAQ Capital Market, or the OTCQB market place of the OTC Markets, then the “Trading Market”
shall mean such other market or exchange on which the Company’s Common Stock is then listed or traded.

 

    2

     

    

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted
for trading on a Trading Market and if prices for the Common Stock are then reported on the OTC Markets, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (c) in all other cases, the fair market value of a share of Common Stock as determined by the Board of Directors of the Company
in good faith.

 

		2.	GENERAL
PROVISIONS.

 

2.1           Loss, Theft, Destruction of Note. Upon receipt of evidence satisfactory
to the Company of the loss, theft, destruction or mutilation of this Note and, in the case of any such loss, theft or destruction,
upon receipt of indemnity or security reasonably satisfactory to the Company, or, in the case of any such mutilation, upon surrender
and cancellation of this Note, the Company will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a
new Note of like tenor and unpaid principal amount dated as of the date hereof. This Note shall be held and owned upon the express
condition that the provisions of this Section 2.1 are exclusive with respect to the replacement of a mutilated, destroyed,
lost or stolen Note and shall preclude any and all other rights and remedies notwithstanding any law or statute existing or hereafter
enacted to the contrary with respect to the replacement of negotiable instruments or other securities without their surrender.

 

2.2           Prepayment; Redemption. This Note may not be prepaid by the Company in
whole or in part, except with the prior written consent of the Holder. This Note may not be redeemed by the Company in whole or
in part, except with the prior written consent of the Holder.

 

		3.	CONVERSION OF NOTE.

 

		3.1	Conversion.

 

(a)              
Conversion upon Tier 1 Qualified Financing. Upon the consummation of a Tier 1 Qualified Financing, at the prior written
election of the holders of a majority of the outstanding principal of the Notes under the Subscription Agreement, the (i) outstanding
principal, (ii) accrued and unpaid interest under the Notes and (iii) the Premium, would be either payable upon demand, or convertible
into shares of New Round Stock based upon the price of the New Round Stock in the Qualified Financing.

 

(b)              
Conversion upon Tier 2 Qualified Financing. Upon the consummation of a Tier 2 Qualified Financing, without any action
on the part of the Holder, the (i) outstanding principal, (ii) accrued and unpaid interest under the Note and (iii) the Premium
shall convert into New Round Stock based upon the price of the New Round Stock in the Qualified Financing.

 

    3

     

    

 

(c)               
No Conversion upon Tier 3 Qualified Financing; Security Interest. Neither the Holder nor the Company may cause the conversion
of this Note upon a Tier 3 Qualified Financing. In the event the Company is unsuccessful in consummating either a Tier 1 Qualified
Financing or a Tier 2 Qualified Financing by March 31, 2017, the Company shall promptly grant to the Holder a security interest
on all of the Company’s assets and shall file a UCC-1 Financing Statement to perfect such security interest, and shall execute
and deliver such other documents, agreements and instruments that the Holder reasonably requires to so grant and perfect the security
interest in the Company’s assets.

 

(d)              
Conversion upon Change of Control. If a Change of Control transaction occurs prior to the Qualified Financing, the (i)
outstanding principal, (ii) accrued and unpaid interest under the Note and (iii) the Premium would, at the election of the holders
of a majority of the outstanding principal of the Notes, be either (A) payable upon demand as of the closing of such Change of
Control transaction or (B) convertible into shares of the Common Stock immediately prior to such Change of Control transaction
at a price per share equal to the lesser of (A) the VWAP, or (B) the per share consideration to be received by the holders of the
Common Stock in such Change of Control transaction.

 

(e)               
Cancellation. Upon and as of the Conversion Date, this Note will be cancelled on the books and records of the Company
and shall solely represent the right to receive the Conversion Shares.

 

		3.2	Delivery
of Securities Upon Conversion.

 

(a)              
As soon as is practicable after a Conversion Date, the Company shall deliver to the Holder a certificate or certificates
evidencing the Conversion Shares issuable to the Holder.

 

(b)              
The issuance of certificates for Conversion Shares upon conversion of this Note shall be made without charge to the
Holder for any issuance tax in respect thereof or other cost incurred by the Company in connection with such conversion and the
related issuance of securities. Upon conversion of this Note, the Company shall take all such actions as are necessary in order
to ensure that the Conversion Shares so issued upon such conversion shall be validly issued, fully paid and nonassessable.

 

3.3          Fractional Shares. No fractional shares or scrip representing fractional
shares shall be issued upon conversion of this Note. If any conversion of this Note would create a fractional share or a right
to acquire a fractional share, the Company shall round to the nearest whole number.

 

		4.	STATUS; RESTRICTIONS ON TRANSFER.

 

4.1           Status of Note. This Note is a direct, general and unconditional obligation
of the Company, and constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms
subject, as to enforcement, to bankruptcy, insolvency, reorganization and other similar laws of general applicability relating
to or affecting creditors’ rights and to general principles of equity. This Note does not confer upon the Holder any right
to vote or to consent or to receive notice as a stockholder of the Company, as such, in respect of any matters whatsoever, or any
other rights or liabilities as a stockholder, prior to conversion hereof into Conversion Shares.

 

    4

     

    

 

4.2          Restrictions on Transferability. This Note and any Conversion Shares issued
with respect to this Note, have not been registered under the Securities Act, or under any state securities or so-called “blue
sky laws,” and may not be offered, sold, transferred, hypothecated or otherwise assigned except (a) pursuant to a registration
statement with respect to such securities which is effective under the Act or (b) upon receipt from counsel satisfactory to the
Company of an opinion, which opinion is satisfactory in form and substance to the Company, to the effect that such securities may
be offered, sold, transferred, hypothecated or otherwise assigned (i) pursuant to an available exemption from registration under
the Act and (ii) in accordance with all applicable state securities and so-called “blue sky laws.” The Holder agrees
to be bound by such restrictions on transfer. The Holder further consents that the certificates representing the Conversion Shares
that may be issued with respect to this Note may bear a restrictive legend to such effect. In addition, this Note shall be subject
to the restrictions on transfer set forth in Article III of the Subscription Agreement.

 

5.            COVENANTS. In addition to the other covenants and agreements of the Company set forth in this Note, the Company covenants
and agrees that so long as this Note shall be outstanding:

 

5.1           Payment of Note. Upon a Maturity Date that is not also a Conversion Date,
the Company will punctually, according to the terms hereof, pay or cause to be paid all amounts due under this Note.

 

5.2           Notice of Default. If any one or more events occur which constitute or
which, with the giving of notice or the lapse of time or both, would constitute an Event of Default or if the Holder shall demand
payment or take any other action permitted upon the occurrence of any such Event of Default, the Company will forthwith give notice
to the Holder, specifying the nature and status of the Event of Default or other event or of such demand or action, as the case
may be.

 

		6.	REMEDIES.

 

		6.1	Events
of Default. “Event of Default” wherever used herein means any one of the following events:

 

(a)              
The Company shall fail to issue and deliver the Conversion Shares in accordance with Section 3;

 

(b)              
Default in the due and punctual payment of the principal of, or any other amount owing in respect of (including interest),
this Note when and as the same shall become due and payable;

 

    5

     

    

 

(c)               
Default in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant
or agreement a default in the performance of which is specifically provided for elsewhere in this Section 6.1), and the
continuance of such default for a period of 10 days after there has been given to the Company by the Holder a written notice specifying
such default and requiring it to be remedied;

 

(d)              
The entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving
as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under
the Federal Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee
or sequestrator (or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up
or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar
days;

 

(e)               
The institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the
institution of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking
reorganization or relief under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to
the filing of any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar
official) of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors;

 

(f)               
The Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an
arrangement or composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension
of payments or other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting
all or any material part of the indebtedness of the Company; or

 

(g)              
It becomes unlawful for the Company to perform or comply with its obligations under this Note.

 

6.2          Effects of Default. If an Event of Default occurs and is continuing, then
and in every such case the Holder may declare this Note to be due and payable immediately, by a notice in writing to the Company,
and upon any such declaration, the Company shall pay to the Holder the outstanding principal amount of this Note plus all accrued
and unpaid interest through the date the Note is paid in full.

 

6.3          Remedies Not Waived; Exercise of Remedies. No course of dealing between
the Company and the Holder or any delay in exercising any rights hereunder shall operate as a waiver by the Holder. No failure
or delay by the Holder in exercising any right, power or privilege under this Note shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power
or privilege. By acceptance hereof, the Holder acknowledges and agrees that this Note is one of a series of Convertible Subordinated
Promissory Notes of similar tenor issued by the Company (collectively, the “Related Notes”) and that
upon the occurrence and during the continuance of any Event of Default, the holders of a majority in original principal amount
of the Related Notes shall have the right to act on behalf of the holders of all such Notes in exercising and enforcing all rights
and remedies available to all of such holders under this Note, including, without limitation, foreclosure of any judgment lien
on any assets of the Company. By acceptance hereof, the Holder agrees not to independently exercise any such right or remedy without
the consent of the holders of a majority in original principal amount of the Related Notes.

 

    6

     

    

 

		7.	MISCELLANEOUS.

 

7.1             
Severability. If any provision of this Note shall be held to be invalid
or unenforceable, in whole or in part, neither the validity nor the enforceability of the remainder hereof shall in any way be
affected.

 

7.2             
Notice. Where this Note provides for notice of any event, such notice
shall be given (unless otherwise herein expressly provided) in writing and either (a) delivered personally, (b) sent by certified,
registered or express mail, postage prepaid or (c) sent by facsimile or other electronic transmission, and shall be deemed given
when so delivered personally, sent by facsimile or other electronic transmission (confirmed in writing) or mailed. Notices shall
be addressed, if to Holder, to its address as provided in the Subscription Agreement or, if to the Company, to its principal office.

 

7.3             
Governing Law. This Note shall be governed by, and construed in accordance
with, the laws of the State of Delaware (without giving effect to any conflicts or choice of law provisions that would cause the
application of the domestic substantive laws of any other jurisdiction).

 

7.4             
Forum. The Holder and the Company hereby agree that any dispute which
may arise out of or in connection with this Note shall be adjudicated before a court of competent jurisdiction in the State of
Delaware and they hereby submit to the exclusive jurisdiction of the courts of the State of Delaware, as well as to the jurisdiction
of all courts to which an appeal may be taken from such courts, with respect to any action or legal proceeding commenced by either
of them and hereby irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding
brought in such a court or respecting the fact that such court is an inconvenient forum.

 

7.5             
Headings. The headings of the Articles and Sections of this Note are inserted
for convenience only and do not constitute a part of this Note.

 

7.6             
Amendments. This Note may be amended or waived only with the written consent
of the Company and the holders of a majority in original aggregate principal amount of this Note and the Related Notes. Any such
amendment or waiver shall be binding on all holders of the Notes, even if they do not execute such consent, amendment or waiver.

 

7.7             
No Recourse Against Others. The obligations of the Company under this
Note are solely obligations of the Company and no officer, employee or stockholder shall be liable for any failure by the Company
to pay amounts on this Note when due or perform any other obligation.

 

7.8             
Assignment; Binding Effect. This Note may be assigned by the Company without
the prior written consent of the Holder. This Note shall be binding upon and inure to the benefit of both parties hereto and their
respective permitted successors and assigns.

 

 

Signature
on the Following Page

 

 

 

    7

     

    

 

In
Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove
written.

 

	 	Bionik Laboratories Corp. 

	 	 
	 	 
	 	By: 	
	 	Name:	  	Peter Bloch
	 	Title:		Chairman and CEO

 

  

Signature
Page to Convertible Promissory Note

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]